Open

Treatment with PUL-042 in Patients with Parainfluenza, Human Metapneumovirus, or Respiratory Syncytial Virus

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of stem cell transplantation with specific viral infections.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will meet with the study team to see if you are eligible to take part in the study. This will include an exam, labs, and a chest X-ray. If you are eligible, you will be randomized to receive either the study drug or a placebo. You will take 3 doses of the treatment (either the study drug or placebo). You will return to clinic after the treatment to follow up with the study team and have exams, labs, and chest X-rays.

In-person visits:
11 visits; 4 visits may be done virtually

Phone or online visits:
4 visits may be done virtually

Total length of participation:
30 days

Looking for Specific Volunteers

Able to participate:

Diagnosis of leukemia, lymphoma, or multiple myeloma; or have received a stem cell transplant for leukemia, lymphoma, multiple myeloma, and myelodysplastic and myeloproliferative disorder
Have been treated with chemotherapy within the past 6 months or are on an immunosuppressive therapy
Have symptoms with an upper or lower respiratory tract infection

Not eligible if:

History of chronic lung disease
Have been treated for fungal, viral, or bacterial pneumonia in the past 30 days
Exposure to any experimental drug in the last 30 days
Significant bacterial or fungal infection

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Janell Markey
janell_markey@med.unc.edu

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Paul Armistead
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Other Cancers, Leukemia, Lymphoma, Multiple Myeloma)
Transplant

IRB Number

25-1596

ClinicalTrials.gov

NCT06665100

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.